Main Article Content
Background and Aims: Galectin-3(Gal-3) is receiving growing attention due to its potential role in heart failure( HF), is an independent predictor of poor outcomes and mortality in patients with HF from risk evaluation to diagnosis, prognosis and therapy. Therefore, it is recommended as a reliable prognostic biomarker in HF that due to epicardial atherosclerosis is the presence of atherosclerotic plaques in diabetic arteries. Cultured cardiomyocytes secrete Gal-3 in response to hypoxia and proinflammatory cytokines. The goal of this study is to assess galectin-3 levels in patients undergoing percutaneous coronary intervention (PCI) following myocardial infarction to know the extent of the possibility of predicting myocardial infarction, this enabled management of the risk factors to prevent the development of thrombosis. Subjects: The current study included 100 samples that divided into two groups the first involved 70 individuals who were patient with myocardial infarction who undergoing elective percutaneous coronary intervention while the second group included 30 samples as a healthy individuals. Using sandwich ELISA method to determine galectin-3 levels for both groups. Results: galectin-3 was measured in sera samples of the study both groups it shows statistically high significant differences(p=0.000) between myocardial infarction patient group with healthy individuals.